Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies (Q34627828)

3 August 2017

1 reference

3 April 2019

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies (English)

1 reference

3 August 2017

1 reference

3 April 2019

1 reference

3 April 2019

2

J. M G. Larkin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21285971

23 November 2024

author name string

M. E. Gore

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21285971

23 November 2024

language of work or name

English

0 references

publication date

1 February 2011

3 references

full work available at URL

3 August 2017

3 April 2019

29 May 2020

https://www.nature.com/articles/6606084.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21285971

https://europepmc.org/articles/PMC3049574

23 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21285971

https://europepmc.org/articles/PMC3049574?pdf=render

23 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21285971

http://www.nature.com/articles/6606084.pdf

23 November 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

http://www.nature.com/articles/6606084

23 November 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

British Journal of Cancer

23 November 2024

published in

2 references

3 August 2017

3 April 2019

104

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

399-406

1 reference

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Estimates of the cancer incidence and mortality in Europe in 2006.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Targeted therapy for metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Global cancer statistics, 2002

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

Immunotherapy for advanced renal cell cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049574

The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol

7 July 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Tyrosine kinases as targets for cancer therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285971

12 December 2020

inferred from PubMed ID database lookup

Resistance revisited: looking back at 10 years of multidrug resistance research

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285971

12 December 2020

inferred from PubMed ID database lookup

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285971

12 December 2020

inferred from PubMed ID database lookup

Sunitinib for the treatment of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

7 January 2021

inferred from DOI database lookup

Cochrane Database of Systematic Reviews

5

(3)

CD001425

C Coppin

2004

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

23 November 2024

11

19

viii45

B Escudier

2008

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

The Cancer Journal from Scientific American

23 November 2024

16

6

S55

RI Fisher

2000

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Journal of Clinical Oncology

23 November 2024

26

2007

25

JR Merchan

2007

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Journal of Clinical Oncology

23 November 2024

44

25

242S

BI Rini

2007

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

Journal of Clinical Oncology

23 November 2024

51

24

128s

JA Sosman

2006

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

23 November 2024

55

21

viii10

CN Sternberg

2010

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6606084

23 November 2024

Identifiers

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference